PARK2 (parkin) is an E3 ubiquitin ligase that plays a central role in mitochondrial quality control through the process of mitophagy — the selective autophagy of damaged mitochondria. Pathogenic mutations in PARK2 cause autosomal recessive juvenile-onset Parkinson's disease (AR-JP), typically with onset before age 40. The loss of parkin function leads to accumulation of dysfunctional mitochondria, increased oxidative stress, and progressive dopaminergic neuron death in the substantia nigra[@parkin2024].
¶ Parkin Protein Structure and Function
Parkin is a 465-amino acid protein containing multiple functional domains:
| Domain |
Position |
Function |
| N-terminal Ub-like (Ubl) |
Residues 1-76 |
Binding to autophagy receptors (p62, HDAC6) |
| RING0 (R0) |
77-140 |
Autoinhibitory; blocks RING1活性 |
| RING1 |
141-227 |
E2-binding, ubiquitin transfer |
| In-Between-RING (IBR) |
228-327 |
Structural; contributes to active conformation |
| RING2 |
328-465 |
Catalytic; contains the HECT-like active site |
Parkin is a RING-type E3 ligase (RING-between-RING architecture):
- E1 enzyme (ubiquitin-activating enzyme) activates ubiquitin in an ATP-dependent manner
- E2 enzyme (ubiquitin-conjugating enzyme, primarily UBC6, UBC7, UBC13) receives ubiquitin from E1
- Parkin (E3) brings E2~Ub complex to the substrate and facilitates ubiquitin transfer
- Ubiquitin chain formation on substrate proteins marks them for degradation or alters their function
¶ Autoinhibition and Activation
Parkin is kept inactive in the cytosol through an intramolecular interaction where RING0 blocks the RING1-E2 binding interface. Activation requires:
- Phosphorylation of Ser65 in the Ubl domain by PINK1 (kinase)
- Ubiquitin binding to the RING0 domain (after PINK1 phosphorylates ubiquitin at Ser65)
- Displacement of RING0 from the active site
- ** conformational change** that allows E2 binding and substrate ubiquitination
flowchart TD
A["Healthy Mitochondria"] --> B["PINK1 imported into IMM"]
B --> C["PINK1 cleaved by MPP/PreP"]
C --> D["Cleaved PINK1 retrogradely exported"]
D --> E["PINK1 rapidly degraded"]
F["Damaged Mitochondria"] --> G["Membrane Potential Lost"]
G --> H["TOM/TIM import blocked"]
H --> I["PINK1 accumulates on OMM"]
I --> J["PINK1 autophosphorylation"]
J --> K["pS65-Ub generated on OMM"]
K --> L["Parkin recruited to OMM"]
L --> M["Parkin phosphorylated at S65 by PINK1"]
M --> N["Parkin activated"]
N --> O["Ubiquitination of OMM proteins"]
O --> P1["Mitophagy Receptor Recruitment"]
O --> P2["p62/SQSTM1 recruits LC3"]
P1 --> Q["Autophagosome Engulfs Mitochondrion"]
P2 --> Q
Q --> R["Lysosomal Fusion → Degradation"]
PARK2 mutations are the most common cause of autosomal recessive PD, accounting for ~50% of familial PD with onset <30 years and ~10-15% of early-onset PD overall. Over 200 pathogenic mutations have been identified throughout the gene.
| Mutation Type |
Frequency |
Effect |
| Exon deletions (exons 3, 4, 5) |
~30% |
Loss-of-function |
| Point mutations |
~40% |
Missense, nonsense |
| Copy number variants |
~20% |
Deletions/duplications |
| Splice site mutations |
~10% |
Exon skipping |
- Homozygous deletions (N-terminal): earlier onset, more severe
- Compound heterozygotes: variable phenotype
- Single heterozygous: typically not sufficient for PD (recessive inheritance)
- Missense variants: variable penetrance; some may be risk factors rather than causal
Step 1: Mitochondrial Damage Sensing
- Loss of mitochondrial membrane potential (Δψm) prevents PINK1 import
- PINK1 accumulates on the outer mitochondrial membrane (OMM)
- PINK1 autophosphorylates and gains full kinase activity
Step 2: Ubiquitin Phosphorylation
- PINK1 phosphorylates both Ser65 on the Ubl domain of parkin AND Ser65 on ubiquitin molecules on the OMM
- pS65-ubiquitin is a unique "eat-me" signal
Step 3: Parkin Recruitment and Activation
- Phospho-ubiquitin binds to the RING0 domain of parkin
- PINK1 phosphorylates parkin's Ubl domain at Ser65
- This relieves autoinhibition; parkin adopts an open conformation
- Parkin can now interact with E2~Ub conjugates
Step 4: Substrate Ubiquitination
- Parkin ubiquitinates multiple OMM proteins:
- Miro1/2 (mitochondrial Rho GTPases) — marks mitochondria for sequestration
- VDAC1/2 (voltage-dependent anion channels) — pore components
- Mfn1/2 (mitofusins) — fusion proteins on OMM
- TOM20, TOM70 (translocase components)
- Pink1 itself (amplification loop)
Step 5: Autophagosome Recruitment
- p62/SQSTM1 binds to polyubiquitin chains via its UBA domain
- p62 also binds LC3 via its LIR domain
- This links ubiquitinated mitochondria to the forming autophagosome
Step 6: Engulfment and Degradation
- Autophagosome membrane extends around the tagged mitochondria
- Fusion with lysosome delivers contents for degradation
- Mitochondrial components are recycled
Parkin ubiquitinates proteins involved in synaptic vesicle dynamics:
- Synaptojanin 1: involved in synaptic vesicle endocytosis
- Synaptic vesicle proteins: direct tagging for quality control
- Rim: active zone protein involved in neurotransmitter release
Dopamine release is specifically impaired in parkin knockout models.
Parkin targets proteins for degradation via the 26S proteasome:
- Pael receptor (GPR37): accumulates in parkin-null mice, causes ER stress
- AIMP1/p43: translational control
- HSP70: co-chaperone with misfolded protein clients
Parkin modulates inflammatory responses:
- Negatively regulates NF-κB signaling
- Regulates TNF-α-induced cell death
- Parkin-deficient cells show exaggerated inflammatory responses
Dopaminergic neurons are particularly vulnerable to parkin loss because:
- High metabolic demand: dopamine synthesis and reuptake are energy-intensive
- Oxidative stress: dopamine oxidation produces reactive quinones
- Mitochondrial stress: nigral neurons have very high mitochondrial density
- Calcium handling: L-type calcium channels create constant calcium influx
| Feature |
Details |
| Age at onset |
Typically 20-40 years (range 3-66) |
| Disease progression |
Slower than idiopathic PD |
| Motor symptoms |
Tremor less common, dystonia more common |
| Non-motor |
Cognitive impairment less frequent early |
| Response to L-DOPA |
Good initial response |
| Psychiatric |
Depression, anxiety common |
| Dystonia |
Limb dystonia at onset in many |
- DAT PET/SPECT: Shows dopaminergic deficit, similar to idiopathic PD
- MRI: Generally unremarkable
- PET for inflammation: May show reduced microglial activation
Restoring parkin expression using AAV vectors:
| Program |
Approach |
Stage |
| AAV-PARK2 |
AAV2/9-delivered PARK2 |
Preclinical |
| AAV10-PARK2 |
High-efficiency CNS delivery |
Preclinical |
Direct pharmacological activation of parkin is challenging because the gain of function requires structural changes. However:
- Cell-permeable parkin mimetics: research stage
- PINK1 activators: indirect activation via PINK1 substrate enhancement
- Ubiquitin chain stabilizers: maintain ubiquitination for longer
| Approach |
Mechanism |
Stage |
| Mitochondrial antioxidants |
Reduce oxidative damage |
Clinical |
| MitoQ |
Targeted CoQ10 delivery |
Phase 2 |
| Bendavia/SS-31 |
Peptide targeting mitochondrial cardiolipin |
Phase 2 |
| Approach |
Mechanism |
Stage |
| Urolithin A |
Induces mitophagy |
Phase 2 (sarcopenia) |
| NAD+ precursors |
Enhances mitophagy via PGC-1α |
Phase 2 |
| AMPK activators |
Stimulate autophagy/mitophagy |
Preclinical |
| Biomarker |
Assessment |
Parkin-Pathway Status |
| Imaging of mitochondrial mass |
PET, MRI spectroscopy |
Elevated in parkin deficiency |
| Oxidized DJ-1 |
Plasma |
Elevated in PD |
| Mitochondrial DNA copy number |
Blood, iPSC |
Altered in mutation carriers |
| PolyUb chains on mitochondria |
Immunohistochemistry |
Reduced in parkin-PD |
- Substrate identification: Comprehensive identification of parkin's physiological substrates
- Non-coding mutations: Are regulatory region variants also pathogenic?
- Epigenetics: How does parkin loss affect the epigenome over time?
- Compensatory mechanisms: What pathways are upregulated when parkin is lost?
- Therapeutic window: How much parkin function needs to be restored?
- [@parkin2024] Parkin and PINK1: mitochondrial quality control in health and disease## See Also